Cargando…
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. R...
Autores principales: | Gorshein, Elan, Matsuda, Kant, Riedlinger, Gregory, Sokol, Levi, Rodriguez-Rodriguez, Lorna, Eladoumikdachi, Firas, Grandhi, Miral, Ganesan, Shridar, Toppmeyer, Deborah L., Potdevin, Lindsay, Toomey, Kathleen, Hirshfield, Kim M., Chan, Nancy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255711/ https://www.ncbi.nlm.nih.gov/pubmed/34248561 http://dx.doi.org/10.1159/000515510 |
Ejemplares similares
-
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
por: Rojas, Veronica, et al.
Publicado: (2016) -
Targetable alterations in invasive pleomorphic lobular carcinoma of the breast
por: Riedlinger, Gregory M., et al.
Publicado: (2021) -
Role of Biomarkers in the Development of PARP Inhibitors
por: Ganguly, Bratati, et al.
Publicado: (2016) -
Roadmap to a Comprehensive Clinical Data Warehouse for Precision Medicine Applications in Oncology
por: Foran, David J, et al.
Publicado: (2017) -
Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers
por: Paratala, Bhavna S., et al.
Publicado: (2016)